HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy-Reference-Cited by-同舟云学术

HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy

Published:2012-01-12 Issue:1 Volume:10 Page:
ISSN:1479-5876
Container-title:Journal of Translational Medicine
language:en
Short-container-title:J Transl Med

Author:

Fountzilas George,Valavanis Christos,Kotoula Vassiliki,Eleftheraki Anastasia G,Kalogeras Konstantine T,Tzaida Olympia,Batistatou Anna,Kronenwett Ralf,Wirtz Ralph M,Bobos Mattheos,Timotheadou Eleni,Soupos Nikolaos,Pentheroudakis George,Gogas Helen,Vlachodimitropoulos Dimitrios,Polychronidou Genovefa,Aravantinos Gerasimos,Koutras Angelos,Christodoulou Christos,Pectasides Dimitrios,Arapantoni Petroula

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/1479-5876-10-10.pdf

Reference73 articles.

1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 365: 1687-1717.

2. Smith I, Chua S: Medical treatment of early breast cancer. III: chemotherapy. BMJ (Clinical research ed. 2006, 332: 161-162. 10.1136/bmj.332.7534.161.

3. Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL: Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol. 2005, 23: 8597-8605. 10.1200/JCO.2005.02.5841.

4. Hershman D, Neugut AI, Jacobson JS, Wang J, Tsai WY, McBride R, Bennett CL, Grann VR: Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. Journal of the National Cancer Institute. 2007, 99: 196-205. 10.1093/jnci/djk028.

5. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN: The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. The oncologist. 2009, 14: 320-368. 10.1634/theoncologist.2008-0230.

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer;Cancer Drug Resistance;2024-06-03

2. The correlation study between TOP2A gene expression in circulating tumor cells and chemotherapeutic drug resistance of patients with breast cancer;Breast Cancer;2024-04-01

3. Automated Prognosis Marker Assessment in Breast Cancers Using BLEACH&STAIN Multiplexed Immunohistochemistry;Biomedicines;2023-11-29

4. Integrative bioinformatics analysis of miRNA and mRNA expression profiles identified some potential biomarkers for breast cancer;Egyptian Journal of Medical Human Genetics;2023-10-19

5. Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer;Breast Cancer Research and Treatment;2022-03-16